Cargando…
TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics
Millions of patients suffer from major depressive disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy. We used a pharmacometabolomics-informed pharmacogenomics research strategy to identify genes associated with metabolites that were related to SSRI respo...
Autores principales: | Gupta, M, Neavin, D, Liu, D, Biernacka, J, Hall-Flavin, D, Bobo, W V, Frye, M A, Skime, M, Jenkins, G D, Batzler, A, Kalari, K, Matson, W, Bhasin, S S, Zhu, H, Mushiroda, T, Nakamura, Y, Kubo, M, Wang, L, Kaddurah-Daouk, R, Weinshilboum, R M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5003027/ https://www.ncbi.nlm.nih.gov/pubmed/26903268 http://dx.doi.org/10.1038/mp.2016.6 |
Ejemplares similares
-
Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics
por: Liu, Duan, et al.
Publicado: (2018) -
ERICH3: vesicular association and antidepressant treatment response
por: Liu, Duan, et al.
Publicado: (2020) -
Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics
por: Ji, Yuan, et al.
Publicado: (2012) -
Current Concepts in Pharmacometabolomics, Biomarker Discovery, and Precision Medicine
por: Beger, Richard D., et al.
Publicado: (2020) -
Pharmacogenomics‐Driven Prediction of Antidepressant Treatment Outcomes: A Machine‐Learning Approach With Multi‐trial Replication
por: Athreya, Arjun P., et al.
Publicado: (2019)